Status:
COMPLETED
NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
It is hypothesized that the NMP22(Nuclear Matrix Protein) Bladder Check ® Test will demonstrate improved sensitivity over that of standard urine cytology for patients with superficial transitional cel...
Detailed Description
Patients who have been previously treated for bladder cancer and are at a high risk for recurrence are being monitored for recurrence every 3 months with urine cytology and cystoscopy as part of stand...
Eligibility Criteria
Inclusion
- · History of pTis, pT1, large (\>2cm) pTa or multiple pTa bladder cancer tumours.
- Written Informed Consent prior to any study-related procedures.
Exclusion
- History of bladder cancer tumours other than those listed in inclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00318266
Start Date
January 1 2006
End Date
May 1 2008
Last Update
August 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre
London, Ontario, Canada, N6A 4G5